By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Pervasis Therapeutics 



Cambridge  Massachusetts    U.S.A.
Phone: n/a Fax:


SEARCH JOBS


Industry
Biotechnology






Company News
Shire plc to Purchase Substantially All Pervasis Therapeutics Assets to Fortify Regenerative Medicine Business for Undisclosed Amount 4/12/2012 7:57:34 AM
Pervasis Therapeutics Announces Positive Preclinical Study Data of Novel Cell Therapy for Treatment of Solid Tumors 4/6/2011 7:49:00 AM
Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting 3/22/2011 7:52:11 AM
Pervasis Therapeutics Receives Orphan Drug Designation in Europe for Vascugel(R) to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis 3/1/2011 8:40:47 AM
Pervasis Therapeutics Receives FDA Fast Track Status for Vascugel(R) to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis 2/8/2011 7:19:25 AM
Pervasis Therapeutics in “Advanced” Talks with Potential Partners for Blood-Vessel Healing Product, CEO Says 2/1/2011 7:08:11 AM
Pervasis Therapeutics to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases 1/20/2011 8:52:28 AM
Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence 1/20/2011 7:57:58 AM
Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 11/8/2010 6:28:17 AM
Pervasis Therapeutics Provides Update on Progress of Clinical Program Targeting Peripheral Arterial Disease 6/22/2010 11:49:41 AM
1234
//-->